Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia

被引：9

作者：

Paul, Suman ^{[1
]}

Tsai, Hua-Ling ^{[1
]}

Lowery, Patrick ^{[1
]}

Fuchs, Ephraim J. ^{[1
]}

Luznik, Leo ^{[1
]}

Bolanos-Meade, Javier ^{[1
]}

Swinnen, Lode J. ^{[1
]}

Shanbhag, Satish ^{[1
]}

Wagner-Johnston, Nina ^{[1
]}

Varadhan, Ravi ^{[1
]}

Ambinder, Richard F. ^{[1
]}

Jones, Richard J. ^{[1
]}

Gladstone, Douglas E. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2020年 / 26卷 / 03期

基金：

美国国家卫生研究院;

关键词：

Chronic lymphocytic leukemia; Haploidentical; Allogeneic blood or marrow transplantation; Post-transplantation cyclophosphamide; Graft-versus-host-disease; STEM-CELL TRANSPLANTATION; BONE-MARROW; WORKING PARTY; EUROPEAN-SOCIETY; HIGH-RISK; DONOR TRANSPLANTATION; PERIPHERAL-BLOOD; FOLLOW-UP; VENETOCLAX; RITUXIMAB;

D O I：

10.1016/j.bbmt.2019.11.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Allogeneic blood or marrow transplantation (allo-BMT) remains the only treatment for chronic lymphocytic leukemia (CLL) with curative potential. Although post-transplantation cyclophosphamide (PTCy) reduces allo-BMT toxicity by decreasing the risk of graft-versus-host disease (GVHD), its effect on CLL allo-BMT outcomes is unknown. We studied 64 consecutive patients with CLL who underwent nonmyeloablative (NMA) haploidentical allo-BMT at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. In this cohort, the 4-year overall survival was 52% (95% confidence interval [CI], 40% to 68%), and progression-free survival was 37% (95% CI, 26% to 54%). Six patients experienced engraftment failure. PTCy prophylaxis was associated with a modest cumulative incidence of 1-year grade II-IV acute GVHD (27%; %95% CI, 15% to 38%) and %%%2-year chronic GVHD (17%; 95% CI, 7% to 26%). We demonstrate that NMA haploidentical allo-BMT with PTCy is a safe and effective treatment option. (C) 2019 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy

引用

页码：502 / 508

页数：7

共 50 条

[21] HLA-haploidentical bone marrow transplantation with high-dose post-transplantation cyclophosphamide (Cy)
Busca, A.
Bruno, B.
Giaccone, L.
Festuccia, M.
Testa, F.
Allione, B.
D'Ardia, S.
Dellacasa, C.
Pecoraro, C.
Marmont, F.
Falda, M.
BONE MARROW TRANSPLANTATION, 2013, 48 : S185 - S185
[22] Impact of the Addition of Antithymocyte Globulin to Post- Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Battipaglia, Giorgia
Labopin, Myriam
Blaise, Didier
Luis Diez-Martin, Jose
Bazarbachi, Ali
Vitek, Antonin
Chevallier, Patrice
Castagna, Luca
Grillo, Giovanni
Daguindau, Etienne
Lopez-Jimenez, Javier
Koc, Yener
Ruggeri, Annalisa
Nagler, Arnon
Mohty, Mohamad
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (09): : 587.e1 - 587.e7
[23] Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Kasamon, Yvette L.
Bolanos-Meade, Javier
Prince, Gabrielle T.
Tsai, Hua-Ling
McCurdy, Shannon R.
Kanakry, Jennifer A.
Rosner, Gary L.
Brodsky, Robert A.
Perica, Karlo
Smith, B. Douglas
Gladstone, Douglas E.
Swinnen, Lode J.
Showel, Margaret M.
Matsui, William H.
Huff, Carol Ann
Borrello, Ivan
Pratz, Keith W.
McDevitt, Michael A.
Gojo, Ivana
Dezern, Amy E.
Shanbhag, Satish
Levis, Mark J.
Luznik, Leo
Ambinder, Richard F.
Fuchs, Ephraim J.
Jones, Richard J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) : 3152 - +
[24] Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Pediatric Acute Lymphoblastic Leukemia: A Curative Option
Yadav, Satya Prakash
Nivargi, Sagar
Chabra, Prashant
Sharma, Anil
Rastogi, Neha
BONE MARROW TRANSPLANTATION, 2018, 53 : 165 - 166
[25] Allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
Mehra, J
Powles, R
Singhal, S
Prendiville, J
Glynne, P
Zomas, A
Hamblin, M
Saso, R
MacKay, H
Swansbury, GJ
Treleaven, J
Catovsky, D
BLOOD, 1995, 86 (10) : 3821 - 3821
[26] T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes
R Devillier
S Bramanti
S Fürst
B Sarina
J El-Cheikh
R Crocchiolo
A Granata
C Chabannon
L Morabito
S Harbi
C Faucher
A Santoro
P-J Weiller
N Vey
C Carlo-Stella
L Castagna
D Blaise
Bone Marrow Transplantation, 2016, 51 : 194 - 198
[27] T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes
Devillier, R.
Bramanti, S.
Fuerst, S.
Sarina, B.
El-Cheikh, J.
Crocchiolo, R.
Granata, A.
Chabannon, C.
Morabito, L.
Harbi, S.
Faucher, C.
Santoro, A.
Weiller, P-J
Vey, N.
Carlo-Stella, C.
Castagna, L.
Blaise, D.
BONE MARROW TRANSPLANTATION, 2016, 51 (02) : 194 - 198
[28] Successful engraftment of haploidentical bone marrow with post-transplantation cyclophosphamide in patients with aplastic anemia
Dang, Brian Norman
De Oliveira, Satiro
Gray, Ashley
Bowles, LaVette
Moore, Theodore Bruce
PEDIATRIC TRANSPLANTATION, 2020, 24 (02)
[29] An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide
Shabbir-Moosajee, Munira
Lombardi, Lindsey
Ciurea, Stefan O.
AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : 541 - 548
[30] Early withdrawal of immunosuppressive therapy in haploidentical bone marrow transplantation with post-transplantation cyclophosphamide increases chronic GvHD and can reduce relapses
Garcia Avila, S.
Cabero, A.
Bermudez, A.
Sanchez Escamilla, M.
Yanez, L.
Celis, M.
Casado, A.
Fernandez, C.
Nunez, J.
Colorado, M.
Lopez-Duarte, M.
Romon Alonso, I.
Richard, C.
Conde, E.
BONE MARROW TRANSPLANTATION, 2017, 52 : S174 - S174

← 1 2 3 4 5 →